Opportunity ID: 283685
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-16-NFRP-IIRA |
| Funding Opportunity Title: | DoD Neurofibromatosis Investigator-Initiated Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 09, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 01, 2016 |
| Current Closing Date for Applications: | Aug 01, 2016 |
| Archive Date: | Aug 31, 2016 |
| Estimated Total Program Funding: | $1,680,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The NFRP Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.
Preclinical Research: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al. A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in research and should be applied. Projects that include research on animal models are required to submit Attachment 8, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines can be found at |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@3eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@3eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00223398 | May 09, 2016 | Aug 01, 2016 | View |
Package 1
Mandatory forms
Optional forms
Share This Post, Choose Your Platform!
About the Author: osnqt
